Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.520
-0.070 (-1.53%)
At close: Sep 15, 2026, 4:00 PM EDT
4.520
0.00 (0.00%)
After-hours: Sep 15, 2026, 4:04 PM EDT
Prelude Therapeutics Revenue
Prelude Therapeutics had revenue of $5.70M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $22.42M, up 220.34% year-over-year. In the year 2025, Prelude Therapeutics had annual revenue of $12.14M with 73.43% growth.
Revenue (ttm)
$22.42M
Revenue Growth
+220.34%
P/S Ratio
20.26
Revenue / Employee
$283,848
Employees
79
Market Cap
465.54M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.14M | 5.14M | 73.43% |
| Dec 31, 2024 | 7.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 231.24M |
| Ginkgo Bioworks Holdings | 132.42M |
| ARS Pharmaceuticals | 116.93M |
| Prothena Corporation | 54.53M |
| Capricor Therapeutics | 11.13M |
| Entera Bio | 42.00K |
PRLD News
- 4 days ago - Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 5 days ago - Prelude Therapeutics receives FDA clearance for PRT13722 IND application - TheFly
- 5 days ago - Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader - GlobeNewsWire
- 5 weeks ago - Prelude Therapeutics Earnings release: Q2 2026 - Filings
- 5 weeks ago - Prelude Therapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Prelude Therapeutics reports Q2 EPS (14c), consensus (19c) - TheFly
- 5 weeks ago - Prelude Therapeutics Slides: Corporate presentation - Filings
- 7 weeks ago - Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline - TheFly